Document is current
Any future updates will be listed below
-
Authors
Wong, Jonathan
Gruber, Emily http://orcid.org/0000-0001-5990-036X
Maher, Belinda
Waltham, Mark http://orcid.org/0000-0001-9623-8133
Sabouri-Thompson, Zahra
Jong, Ian
Luong, Quinton
Levy, Sidney
Kumar, Beena
Brasacchio, Daniella
Jia, Wendy
So, Joan
Skinner, Hugh
Lewis, Alexander
Hogg, Simon J.
Vervoort, Stephin
DiCorleto, Carmen
Uhe, Micheleine
Gamgee, Jeanette
Opat, Stephen http://orcid.org/0000-0002-0308-6458
Gregory, Gareth P.
Polekhina, Galina http://orcid.org/0000-0001-9535-9291
Reynolds, John http://orcid.org/0000-0002-8825-8625
Hawkes, Eliza A.
Kailainathan, Gajan
Gasiorowski, Robin http://orcid.org/0000-0003-1225-8757
Kats, Lev M. http://orcid.org/0000-0001-8742-8138
Shortt, Jake http://orcid.org/0000-0003-3185-6488
-
Funding
Funding for this research was provided by:
Victorian Cancer Agency (ECSG17003)
Cancer Council Victoria (GNT1187689, GNT1187689)
Department of Health | National Health and Medical Research Council
Medical Research Future Fund
- License Information
-
More Information
Article History
Received: 23 November 2021
Revised: 28 March 2022
Accepted: 4 April 2022
First Online: 22 April 2022
Competing interests
: JS has received research funding from Astex Pharmaceuticals Inc. related to the published work. All other disclosures for JS and co-authors are outside of the published work. JS has received research funding from Amgen and Bristol Myers Squibb/Celgene; JS has served on Advisory Boards for Novartis, BMS, Mundipharma and Astellas. RG has received honoraria from Merck Sharp & Dohme, Takeda, Novartis, AbbVie and Astellas. EAH has provided consultancy to Specialised Therapeutics; EAH has received research funding from Bristol Myers Squibb/Celgene, Merck KGaA, Astra Zeneca and Roche; EAH has received speakers bureau from Roche, Astra Zeneca, Janssen, Regeneron and Abbvie; EAH has served on Advisory Boards for Roche, Antigene, Bristol Myers Squibb and Astra Zeneca and has received travel expenses from Roche. LMK has received research funding and consultancy fees from Agios Pharmaceuticals and Celgene. JR has received research funding from AbbVie and is a shareholder in Novartis AG and Alcon. GPG has served on Advisory Boards for Roche, Novartis, Janssen and Gilead; GPG has received honoraria/speakers’ bureau from Roche, Novartis, Janssen and Astra Zeneca; GPG has received research funding from Beigene, Merck, Abbvie and Janssen; GPG has received travel funds from Roche and Novartis. SO has provided consultancy to AbbVie, Astra Zeneca, Janssen and Roche; SO has received research funding from Amgen and Beigene; SO has received honoraria from AbbVie, Astra Zeneca, Celgene, CSL Behring, Gilead, Janssen, Merck, Roche and Takeda; SO has served on Advisory Boards for AbbVie, Astra Zeneca, Celgene, CSL Behring, Gilead, Janssen, Merck, Roche and Takeda. The other authors have no COI to disclose.
